Adeena Musheer, Operations Coordinator and Educational Committee Member at MedNews Week, shared Yan Leyfman’s, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, post on X, adding:
“Dr. Elad Sharon’s keynote underscored how advances in biomarker research, translational immunology, and immune-related toxicity management are becoming integral to the future of cancer care.
Link to full episode.”
Quoting Yan Leyfman’s post:
“MedNews Week Keynote Conference | Connecting Medicine Globally.
Immunotherapy has transformed the future of cancer care – but with that progress comes one of oncology’s most complex challenges: understanding and managing immune-related toxicities.
Join MedNews Week for our next global keynote conference featuring:
Dr. Elad Sharon.
Clinical and Translational Director of the Immunotherapy Toxicity Program,
Dana-Farber Cancer Institute.
Dr. Sharon is a nationally recognized leader in immuno-oncology, immune-related adverse events, and translational toxicity research. His work has helped advance biomarker-driven approaches to predicting, monitoring, and managing immunotherapy complications across clinical trials and cancer care.
In his keynote,
‘The Dual-Edged Sword: Navigating the Intersection of Immunotherapy and Autoimmunity,’
Dr. Sharon will explore how we can continue expanding the promise of immunotherapy while better recognizing, preventing, and treating the autoimmune and inflammatory complications that can accompany it.
This session is designed for oncologists, hematologists, fellows, residents, medical students, researchers, and anyone interested in the evolving intersection of cancer immunotherapy, autoimmunity, and patient safety.
Date: July 7, 2026
Time: 12:30 PM EST
Episode: The Link
At MedNews Week, our mission is to connect medicine globally – bringing world-class experts, emerging science, and accessible medical education to learners and clinicians across borders.
Join us for a powerful discussion at the frontiers of immunotherapy, toxicity, and global oncology education.”
Other articles featuring Adeena Musheer and Yan Leyfman on OncoDaily.
